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AKTIVITI ANTIKANSER OLEH NANOPARTIKEL PERAK YANG DISINTESIS 
OLEH EKSTRAK AKUEUS Catharanthus roseus  
ABSTRAK 
Nanopartikel perak (AgNPs) semakin banyak digunakan dalam aplikasi bioperubatan 
kerana aktiviti antimikrob yang luar biasa mereka. Walau bagaimanapun, aktiviti anti-
kanser daripada AgNPs kekal akan disiasat. Kajian ini bertujuan untuk menilai aktiviti in 
vitro anti-kanser AgNPs terhadap sel kanser Jurkat (T-sel leukemik) dan HT29 (kolorektal 
kanser). AgNPs biogenik telah disintesis menggunakan ekstrak akueus daun Catharanthus 
roseus (C. roseus). Aktiviti proliferatif C. roseus-AgNPs telah dikira menggunakan MTS 
assay, diikuti dengan pengesanan apoptosis menggunakan annexin-FITC/propidium iodida 
assay dan aktiviti kitaran sel menggunakan kitaran sel assay. Nilai IC50 C. roseus-AgNPs 
terhadap sel Jurkat adalah dalam julat 1.96 hingga 626 μg/mL (median = 5.87 μg/mL) pada 
pelbagai masa inkubasi. Sementara itu, nilai IC50 terhadap sel HT29 adalah dalam julat 
12.99 hingga 13.39 μg/mL (median = 13.19 μg/mL) pada pelbagai masa inkubasi. Sebagai 
perbandingan, nilai IC50 ekstrak akueus C. roseus pada sel-sel Jurkat berada dalam julat 
23.43 hingga 700.00 μg/mL (median = 361.72 μg/mL) manakala nilai IC50 terhadap sel 
HT29 adalah dalam julat 191.47 hingga 888.00 μg/mL (median = 419.26 μg/mL) pada 
pelbagai masa inkubasi. Peratusan yang tinggi bagi kedua-dua apoptotik awal dan lewat 
dikesan terhadap sel Jurkat berbanding terhadap sel HT29 pada pelbagai masa inkubasi, 
sebagai tindak balas kepada C. roseus-AgNPs. C. roseus-AgNPs dan ekstrak akueus C. 
roseus telah merencat fasa S terhadap sel Jurkat pada setiap inkubasi manakala pada HT29, 
C. roseus-AgNPs dan ekstrak akueus C. roseus telah merencat sama ada fasa G0/G1 dan S 
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di pelbagai inkubasi. Hasil kajian menunjukkanC. roseus-AgNPs mempunyai potensi untuk 
digunakan sebagai agen anti-kanser, terutama pada leukemia dan kanser usus. 
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ANTICANCER ACTIVITY OF SILVER NANOPARTICLES SYNTHESISED BY 
Catharanthus roseus AQUEOUS EXTRACT 
ABSTRACT 
Silver nanoparticles (AgNPs) are increasingly used in biomedical applications because of 
their remarkable antimicrobial activity. However, the anticancer activity of AgNPs remain 
to be investigated. The present study was aimed to evaluate in vitro anticancer activity of 
AgNPs on Jurkat (leukemic T-cells) and HT29 (colorectal cancer) cancer cell lines. The 
biogenic AgNPs were synthesised using Catharanthus roseus(C. roseus) leaf aqueous 
extract. The proliferative activity of C. roseus-AgNPs was measured using MTS assay, 
followed by the detection of apoptosis using annexin-FITC/propidium iodide assay and cell 
cycle activity using cell cycle assay. The IC50 values of C. roseus-AgNPs on Jurkat cells 
were in the range of 1.96 to 6.26 µg/mL (median = 5.87 µg/mL) at various incubation 
times. Meanwhile, the IC50 values on HT29 cells were in the range of 12.99 to 13.39 µg/mL 
(median = 13.19 µg/mL) at various incubation times. In comparison, the IC50 values of C. 
roseus aqueous extract on Jurkat cells were in the range of 23.43 to 700.00 µg/mL (median  
= 361.72 µg/mL) while the IC50 values on HT29 cells were in the range of 191.47 to 888.00 
µg/mL (median = 419.26 µg/mL) at various incubation times. Higher percentages of both 
early and late apoptotic cells were detected with for Jurkat cells compared to HT29 cells at 
various incubation times, in response to either C. roseus-AgNPs or C. roseus aqueous 
extract. C. roseus-AgNPs and C. roseus aqueous extract have arrested S phase in Jurkat 
cells at all incubations while in HT29, the C. roseus-AgNPs and C. roseus aqueous extract 
have arrested  either G0/G1 and S phase at various incubations. The findings indicate that 
the C. roseus-AgNPs have a potential to be used as anticancer agents, particularly on 
leukemia and colon cancer. 
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CHAPTER 1 
INTRODUCTION 
 
1.1   Research Background 
Nano oncology is the new field of research knowledge that has potential to be 
used in the detection, target and treatment of the cancer (Jacob et al., 2013). Nanoscale 
treatment is advantageous as compared to the micro-sized anticancer drugs since it is 
more stable and specific, long shelf life, and required only limited dose frequency 
(Jacob et al., 2013, Rajesh and James, 2009). This is due to their unique characteristics 
such as large surface area per volume ratio, porosity, solubility, increased 
bioavailability and different structural properties. The small sized nanoparticles also 
make it able to pass through the cellular barriers and strongly interacts with functional 
biomolecules (Gnanasekar et al., 2014). These characteristics make them as a 
favourable choice to overcome the limitations of conventional cancer therapy, for 
instance less effectiveness of the chemotherapeutic drugs to reach the targeted sites 
(Boca et al., 2011, Shakti et al., 2013). 
 
A report provided by Bhattachryya et al. (2011) has summarised the list of 
nanoparticle-derived drugs with their product names in different phase of clinical 
development including iron oxide nanoparticles (Combidex) for cancer imaging, TNF-a 
bound PEGlyated colloidal gold particles (Aurimmune) for solid tumors and nano-sized 
calcium phosphate (Biovant) for vaccine component whereas albumin-bound paclitaxel 
particles (Abraxane) have been approved by Food and Drug Administration (FDA) to 
be applied for the treatment of non-small cell lung carcinoma and breast cancer. The 
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mechanisms of cytotoxicity for each type of nanoparticles were found to be different 
and thus, the application differs from each other. 
 
Among various types of nanomaterials, silver are advantageous in regards with 
their unique properties, that include conductivity, stability, catalytic and antibacterial 
property (Jeyaraj et al., 2013). Silver nanoparticles (AgNPs) can be defined as 
nanoscale metals sized within 1 to 100 nm (Sukumaran and Eldho, 2012) and have been 
widely used in biomedical applications including as anti-inflammatory, antioxidant, 
antimicrobial and antibacterial agents towards many bacterial genera include 
Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, (Saranyaadevi 
et al., 2014). It has been widely used in medical devices, catheters, dental fillers, wound 
dressing and also for therapeutic purposes (Sangiliyandi et al., 2013b). However, the 
potential applications of these silver nanoparticles as anticancer agents are still new and 
remain to be investigated. 
 
Previous studies have documented the cytotoxicity effects of AgNPs on various 
cancer cell lines with promising results. For example, silver nanoparticles have been 
proven to be biocompatible to healthy cells and has inhibitory effects on the 
proliferation of various cancer cell lines (Boca et al., 2011) including human 
glioblastoma cells (AshaRani et al., 2009), Dalton’s lymphoma ascites (DLA) cell lines 
(Muthu et al., 2010, Jacob et al., 2013), human cervical carcinoma cell lines 
(Karunamoorthy et al., 2014), breast carcinoma MCF-7 cell lines (Ramy and Hashem, 
2014, Gnanasekar et al., 2014), HeLa cell lines (Panchanathan et al., 2013), MDA-MB-
231 cell lines (Sangiliyandi et al., 2013a) and human lung cancer A549 cell lines  (Renu 
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et al., 2013, Balaji et al., 2014). These preliminary data suggests that AgNPs have great 
potentials to be applied as anticancer agents. 
 
AgNPs can be produced using physical and chemical methods. These methods 
are carried out by using hazardous chemicals such as sodium borohydride, potassium 
bitartrate, methoxypolyethylene glycol and hydrazine which are responsible to reduce 
their sizes into nanoscale particles. However, these chemicals are highly toxic to human 
(Sukumaran and Eldho, 2012). According to Hazardous Substance Fact Sheet issued by 
New Jersey Department of Health and Senior Services, sodium borohydride can cause 
acute irritation and burn to skin, eyes, nose, throat and lungs. It can also cause severe 
shortness of breath and affects the nervous system for long term exposure.  Moreover, 
they are not environmental friendly and expensive (Prabhu et al., 2014). Therefore, 
green synthesis of AgNPs using bacteria, fungi or plants has gained attention and focus 
of research. Amongst these methods, plant-synthesized AgNPs have been shown to be 
quicker in reaction as compared to microbes (Sukumaran and Eldho, 2012). Moreover, 
these methods are less toxic, cost effective and environmental friendly (Ghassan et al., 
2013). 
 
As for a preliminary study, AgNPs synthesised by Catharanthus roseus 
aqueous extract were used to evaluate its in vitro anticancer activity towards two models 
of human cancer cells which were Jurkat (leukemic T-cells) and HT29 (colorectal 
carcinoma) cancer cell lines. Previous study done by Nor Hazwani et al. (2010) has 
shown that C. roseus aqueous has significant inhibitory effects on Jurkat cell. Therefore, 
a comparison between the cytotoxic effects of C. roseus aqueous extract and C. roseus-
AgNPs on similar cell line should be evaluated. Previous studies also have reported on 
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the effects of silver nanoparticles on HT29 cells, but to the best of our knowledge, there 
was no report the on AgNPs synthesised by C. roseus being tested on HT29 (Devi and 
Bhimba, 2012, Sanpui et al., 2011, Devi and Bhimba, 2013, Arunachalam et al., 2015). 
The basic research and knowledge about their effects on specific cells are important to 
provide useful information in developing an improved quality and effectiveness of 
anticancer treatment. 
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1.2 Research Objectives 
The main objective of this study was to evaluate the anticancer activity of C. roseus-
AgNPs on Jurkat and HT29 cancer cell lines. The specific objectives are as follow: 
1. To examine the effects of C. roseus-AgNPs on the proliferation of Jurkat and 
HT29 cells 
2. To analyse detection of early and late apoptosis mechanism of Jurkat and 
HT29 cells treated with C. roseus-AgNPs 
3. To analyse the cell cycle of Jurkat and HT29 cells treated with C. roseus-
AgNPs 
6 
 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1.    Cancer Statistic 
Cancer is among the most prevalent disease and one of the main killers 
worldwide. In a cancer statistics provided by the National Cancer Registry (NCR) 
Malaysia, the highest reported cancer cases were among Chinese with 50.66 percent, 
followed by Malays and Indians which were 42.93 percent and 6.41 percent, 
respectively. This data also showed that women dominated the percentage by 10.8 
percent higher compared to men among 18,219 reported cases of cancer (Zainal and 
Nor Saleha, 2011). According to the World Health Organization (WHO), 14.1 million 
of new cancer cases were estimated being reported to occur worldwide and the number 
were expected to increase by 2030.  From 100,000 populations, 205.4 cancer 
occurrences were reported in men and 165.3 in women in 2012. Among all the cancer 
death reported, lung, breast, bowel and prostate cancer were recorded as the most 
common causes in worldwide (International Agency for Research on Cancer, 2012, 
World Health Organization, 2014, Torre et al., 2015). 
 
Leukaemia was the seventh most prevalent cancer among adult age and the 
most common happened in children. National Cancer Registry of (NCR) Malaysia has 
reported that leukaemia covers 4.1 percent from 741 cancer cases in 2007 where 490 
(66.1%) cases were on 50 years and above patients and the rest that constitute 251 
(33.9%) were on children in the range age of 0-14 years old. From this statistic, male 
patient were higher in percentage compared to female. From the 741 cases, 266 (35.9%) 
cases reported on adult men and 224 (30.2%) cases were on adult women. Male 
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children constitute 153 (20.6%) cases followed by female children that are 98 (13.2%) 
cases. In term of races population, Malays dominate the percentage with 425 cases 
followed by Indians with 259 cases and the least was Chinese with 57 cases (Zainal and 
Nor Saleha, 2011). 
 
National Cancer Registry (NCR) Malaysia reported that colorectal cancer is 
the second most common in Peninsular Malaysia after breast cancer. For the male 
population, this cancer was the second most prevalent after trachea, bronchus and lung 
cancer while for female the second after the breast cancer. Colorectal cancer represents 
12.3 percent among 18,219 cases registered to NCR in 2007 (Zainal and Nor Saleha, 
2011). In the another annual report by National Cancer Patient Registry-Colorectal 
Cancer that collect the data from October 2007-2008, 60 percent of the total 622 
patients were male and the rest were female. From the total registered cases of 
colorectal cancer, the mean age calculated were 61 years old from the range of 15 to 95 
years old of overall age of patients. However, the majority of the patients which 
constitute 81 percent were aged 50 years and above (Muhammad Radzi and Wendy, 
2010).  
 
2.2   Cancer Treatment 
Conventional treatments that were used to treat or fight cancer include surgery, 
chemotherapies and radiotherapies, immunotherapy, targeted therapy, transplantation, 
cryosurgery, hyperthermia and photodynamic therapy (Torre et al., 2015). However, 
these conventional therapies were known having many side effects. For example, 
chemotherapies were not only kills the cancerous cell but also kill healthy dividing 
cells. This is due to its non-specific action, high toxicity effects and ability to enhance 
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the development of resistance of the cancerous cells toward the drugs after long-term 
treatment (Takeuchi and Alison, 2008). Other adverse effects of chemotherapies include 
thrombocytopenia, neutropenia and anaemia that can cause bleeding, infections, fluid 
retention, diarrhoea and urinary, kidney and bladder changes in worst case patients 
(International Agency for Research on Cancer, 2012, World Health Organization, 2014, 
Torre et al., 2015). 
 
Radiotherapy has the capacity to cause shrinkage and damage of the tumour in 
a short period of time and that makes it as another common conventional treatment for 
cancer. However, like chemotherapy, the action of radiotherapy is not specific and can 
cause toxicity effects to the patients. Despite killing the cancerous tissues, it also can 
cause inhibition in healthy cells and induce resistance and mutation upon long-term 
exposure (Tolentino et al., 2011). In addition, the ionizing radiation of the radiotherapy 
can also induce damages or changes in oral mucosa, skin and salivary glands in normal 
tissues of nearby area. Furthermore, older patients and children usually have undesirable 
significant side effects and life threatening effects after treatment (Tolentino et al., 
2011, Otmani, 2007). 
 
Another therapy that is used in cancer treatment is immunotherapy which used 
monoclonal antibody (mAb) or cytokine to specifically target the cancerous cells or 
boosting the immune system to fight against tumour. However, immunotherapy 
produces different response in different patients and the treatment also takes longer time 
that is about 3 to 5 years thus makes it expensive. Other than that, the effectiveness of 
the treatment also may reduced as the target tumour or fields changed. The side effect of 
immunotherapy is it can induce severe, life threatening, anaphylactic reactions 
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(Kirschner and Panetta, 1998). Immunotherapy was commonly used in late stage cancer 
treatment such as after radiotherapy, surgery or chemotherapy where the immune 
system of the patients is weakened due to the earlier conventional treatment (Jahrsdörfer 
and Weiner, 2008). 
 
Due to the limitations of conventional treatment, many studies have been done 
involving nanotechnology and nanomaterials especially in nanoparticles to overcome 
the problems. One of the examples was the use of nano sized particles that has been 
widely used in drug delivery system for chemotherapeutic agents against cancer cells 
(Mirkin et al., 2011). 
 
2.3   Nanotechnology 
Nanotechnology is the development of technology in creating nanoscale 
devices, systems and materials that sizes range from 1-100 nm. These nanoscale 
products are unique in terms of physicochemical properties compared to their 
macroscale size (Cristina et al., 2011). Nanotechnology that is applied in the field of life 
sciences technology or biotechnology creates the term nanobiotechnology. Examples of 
applications of nanobiotechnology are nanosurgery, nanolasers for cellular surgery and 
nano robots. Nanobiomedicine is also one of the applications of nanobiotechnology that 
specifically relates with medicine. Nanobiomedicine includes the use of nanodevices for 
diagnosing patients, nanocarrier drug delivery system and also nanopharmaceutical 
(Jain, 2010). Other than that, production of inert metallic nanoparticles that has potential 
in therapeutic application like silver, platinum and gold also includes in the application 
of nanomedicine (Jayachandra et al., 2014). 
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Another most important branch of nanomedicine is the nanooncology that 
relates with tumor management. Some of the examples of nanooncology applications 
are in the diagnosis of cancer using quantum dots, detecting cancer cell using gold 
nanoparticles conjugated with monoclonal antibody, nanobiosensors to detect multiple 
protein biomarkers of cancer, magnetic nanoparticles to attach and detect the floating 
cancer cell in blood circulation and target delivery of drugs to cancerous site by 
nanocarrier (Jain, 2010). 
 
Nanoparticles or nano treatment is emerging as a new approach in cancer 
treatment because of their unique physical and chemical characteristics. They are very 
small in size thus makes them have large surface area to volume ratio. This property 
enables nanoparticles to pass through the cellular barrier easily and also able to 
efficiently carry conjugated compounds such as drugs, nucleic acids, antibody, proteins 
and probes (Thakor and Gambhir, 2013).  Moreover, the nano treatment also more 
favoured because of their characteristics such as longer shelf life, more stable, specific 
and only needed in low dosage frequency compared to conventional treatment (Jacob et 
al., 2013). The examples of nanoparticles derived drugs in the different phase of clinical 
development were illustrate in Table 2.1. 
 
2.3.1   Biomedical Application of Nanomaterials 
Nanomaterials were already being used widely in medical practice such as in 
invasive imaging techniques, targeted drug delivery systems and in the development of 
engineered organs. Table 2.2 shows that various type and structure of nanomaterials that 
has been used in biomedical applications. An example, nanoscaled drug delivery 
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systems such as liposomes and drug-conjugated nanoparticles were used for cancer 
treatment in drug chemotherapy (Barkalina et al., 2014, Ulatowska-Jarza et al., 2011). 
 
 
Products Combidex 
(Ferumoxtran-
10) 
Biovant CYT-6091 
(Aurimmune) 
Bio-
conjugated 
nanoparticles 
Abraxane 
Type of 
nano 
materials 
Iron oxide 
nanoparticles 
Nano sized 
calcium 
phosphate 
TNF-α bound 
PEGlyated 
colloidal gold 
particle 
Luminescent 
quantum dots 
Albumin-
bound 
paclitaxel 
particles 
Size (nm) 17-20 NAD 33 10-15 130 
Application Tumor imaging Vaccine 
component 
Solid tumors Cancer 
imaging 
NSC lung 
cancer, 
breast 
cancer, 
others 
Route of 
administrati
on 
IV IM IV Subc IV 
Phase NDA field Phase I 
completed 
Phase I Preclinical Approved 
Company Advanced 
Magnetics 
BioSante 
Phamaceuti
cal 
Cytlmmune 
Sciences 
Emory-
Georgia tech 
nano-
technology 
centre 
Abraxis 
Oncology 
 
The drugs that were conjugated with biocompatible polymers were found to reduce the 
systemic toxicities and inducing the possible reformulation of existing drugs. The 
example was Polyethylene glycol (PEG) coated liposomes that conjugated with 
anthracycline doxorubicin that shows an effective effect against doxorubicin-resistant 
colorectal cancer. In order to encourage sufficient mechanical strength, expanding 
cellular growth and maximizing the potential of osseointegration, nanoparticles-
conjugated polymer are used to induce the reinforcement of the structure (Loizidou and 
Seifalian, 2010, Nie et al., 2007). 
 
Table 2.1 Nanoparticle derived drugs in the different phase of clinical development. 
Table taken from Bhattacharyya et al. (2011) 
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Table 2.2 Biomedical applications of nanomaterials. Table was taken from Barkalina 
et al. (2014) 
Furthermore, the ability of bacteria to develop resistance against antibiotics 
after extended time encourages the development of new strategies in order to cope with 
the implant related infections. Therefore, silver that were known to have antibacterial 
activities were used in silver-based biomaterial to overcome this limitations. The 
characteristic makes the silver-based materials to be used worldwide to protect the inner 
and outer surfaces and the proximity of a medical device to protect the implant from 
infection (Eckhardt et al., 2013). 
 
 
Class Subclass Material Structure Description 
Organic Lipid Phospholipids Liposome Enclosed nanospheres 
comprised of a 
phospholipid bilayer 
 Micelles Enclosed nanospheres 
comprised of a 
phospholipid monolayer 
Solid lipid Solid lipid 
nanoparticles 
Nanospheres comprised 
of the lipid core 
stabilized by surfactants 
and/or polymers 
Polymers Poly-L-
lactide-co-
glycolide 
(PLGA) 
Nanoparticles Variously shaped 
structure with all three 
physical dimensions on 
the nanoscale (< 100 nm) 
Poly-L-lactic 
acid (PLA) 
Chitosan 
Gelatine 
Polyamidoami
ne (PAMAM) 
Dendrimers Spherical nanomolecules 
consisting of the central 
core and sequential 
layers of branching 
groups 
Polypropylene
imine (PPI) 
Inorganic 
 
Noble 
metals 
Gold Nanoparticles Various shaped structures 
with all three physical 
dimensions on the 
nanoscale (< 100 nm) 
Silver 
Platinum 
Oxides Magnetic and 
superpara 
magnetic iron 
Nanoparticles Various shaped structures 
with all three physical 
dimensions on the 
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oxides nanoscale (< 100 nm) 
Semicond
uctors 
Cadmium Quantum dots Semiconductor 
nanocrustals with optical 
properties 
Selenium 
Tellurium 
Indium 
Carbon-
based 
Carbon Fullerences Hollow nanospheres, 
comprised of carbon 
atoms, forming cage-like 
structure 
Nanotubes Cylindrical structures 
with two of three 
physical dimensions on 
the nanoscale (< 100 nm) 
Other Mesoporous 
silica 
Nanoparticles Various shaped structures 
with all three dimensions 
on the nanoscale (<100 
nm) and mesoporous 
architecture (pore 
diameter: 2-50 nm) 
 
2.3.2   Silver Nanoparticles (AgNPs) 
Silver is a type of inert inorganic metal element that exists naturally in 
environment. Silver ions are the product of ionisation of silver metal that can kill 
microbes. Silver was found to have medicinal properties since hundred years ago and 
being used as antibacterial and antimicrobial agent long before the discovery of 
microbial agent during the Germ Theory of Disease (Barillo and Marx, 2014). The 
earliest usage of silver is as silver vessels or in the form of coins to store and disinfect 
water. This was followed by other medicinal application such as antiseptics and use in 
burn and wound care (Barillo and Marx, 2014, Gao et al., 2015). 
 
The development of nanotechnology nowadays makes the silver metal being 
able to be produced in nanoscale particles with sizes less than 100 nm. The 
nanoparticles form of silver enhanced in physical, chemical and biological properties 
when compared to its bulky form (Muthu et al., 2010). AgNPs are more favourable due 
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to their characteristics such as chemically stable, reliable, cheap in production, have 
catalytic properties in chemical reaction, good conductivity, anti-inflammatory, and 
antimicrobial activity against various infectious bacteria includes Staphylococcus 
aureus, Escherichia coli and Pseudomonas aeruginosa (Saranyaadevi et al., 2014, Hunt 
et al., 2014). They kill the microbes by disrupting the respiratory function and 
permeability of cell and destruct the DNA to inhibit the growth of the microbes 
(Mohammed, 2015). 
 
Thus, the properties make them not only being applied in many consumers 
products, food production or cosmetics but also in medical and biomedical field 
including in wound dressing, as antiseptics, dental fillers and as a coating materials on 
medical devices to prevent biofilm production by bacteria (Garvita et al., 2014). Silver 
nanoparticles were proven having high toxicity towards many microorganisms. 
However, they were found to be less or non toxic towards human and other mammalian 
cells at low concentration (Jacob et al., 2013, Garvita et al., 2014). 
 
In recent findings, AgNPs were recorded to have inhibitory effect on the 
proliferation against several cancers in vitro. This include breast cancer MCF-7 cell 
lines (Khatiravan et al., 2014, Gnanasekar et al., 2014), Dalton’s lymphoma ascites 
(DLA) cell lines (Muthu et al., 2010), human lung carcinoma A549 cell lines (Renu et 
al., 2013, Balaji et al., 2014), human cervical carcinoma cell lines (Karunamoorthy et 
al., 2014, Panchanathan et al., 2013), colo205 cell line (Garvita et al., 2014) and human 
glioblastoma cell lines (AshaRani et al., 2009). 
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The nanoscale size makes them to become chemically active and produced 
reactive oxygen species (ROS) and free radicals that can cause inflammation and 
damage to the cell. Studies proved that silver nanoparticles can cause oxidative stress 
and damage on genetic material when they get into sarcoma cells, primary neural cells 
and carcinoma cells by inducing the production of reactive oxygen species. Other than 
that, silver nanoparticles also proved to induce apoptosis on cells by increasing the 
tumor suppressor gene expression (Rajanahalli et al., 2015). 
 
There are several ways to produced silver nanoparticles. In early technology, 
silver nanoaparticles were produced through physical and chemical method (Renu et al., 
2013). The disadvantage of physical method is the low yield production while for 
chemical method; it is also less preferred because it requires the usage of harmful and 
toxic chemical such as sodium borohydride and citrate to reduce the silver ions to 
nanoparticles form (Sangiliyandi et al., 2013b). The by-products from this method also 
are harmful to the environment. In addition, the methods also costly  and need a specific 
condition to produce the nanoparticles (Rajan et al., 2015). 
 
Nowadays, green method of production of silver nanoparticles gains more 
attention over the early method. Green method includes the use of bacteria, fungi and 
plant extracts as the reducing agent for silver ions (Khatiravan et al., 2014). In general, 
green method are more preferable because of they are safer to the environment, need 
less cost of production, not require specific condition and can produce in large quantity 
(Garvita et al., 2014). However, above all the green methods, plant aqueous extract are 
the one that is most preferable because it not require any cell culture method that can 
have the risk of contamination occurring (Khatiravan et al., 2014). Moreover, the waste 
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product of microorganisms needs to be properly managed because it may harmful to the 
environment depending on the types of microorganisms used. The production using 
plant aqueous extract also can be very simple and fast because plants contains high 
reduction potential compared to other two methods. The alkaloids and phytochemicals 
that present in the plant extract also can give the effect of stability towards the 
nanoparticles that were produced (Rajan et al., 2015). 
 
There are many reports that show the production of silver nanoparticles from 
plant extract including Melia dubia (Khatiravan et al., 2014), Acorous calamus 
(Jayachandra et al., 2014), Moringa olifera (Karunamoorthy et al., 2014), Ficus 
religiosa (Jacob et al., 2013), Eucalyptus chapmaniana (Ghassan et al., 2013), Sesbania 
grandiflora (Jeyaraj et al., 2013), Eucalyptus globulus, Ziziphus spina-christi, 
Eucalyptus angophoroides, Camellia sinensi, Eucalyptus camaldulensis (Mohammed, 
2015), Origanum vulgare (Renu et al., 2013) and Catharanthus roseus (Mukunthan et 
al., 2011). Almost all of these biosynthesized silver nanoparticles exhibit anticancer 
activity towards various cancer cell lines. 
 
2.4   Catharanthus roseus (L) G. Don 
Catharanthus roseus (L) G. Don or also known as Vinca rosea as shown in 
Figure 2.1 is an important medicinal plant from Apocynaceae family that wildly grows 
in tropical and subtropical climate (Dutta et al., 2005). This Madagascar periwinkle is a 
type of flowering herbaceous plant that usually grows upright or decumbent, up to one 
metre height and secretes latex that produces pungent odour when damaged. Despite 
being used as ornamental plant, Catharantus roseus (C. roseus) also were known as an 
important therapeutic plant that was used traditionally to cure various diseases including 
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diabetes, leukaemia, insect bites, dysentery, and skin infection (Nejat et al., 2015, 
Pankaj et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
C. roseus produces more than 120 terpenoids indole alkaloids (TIAs) including 
vinblastine, vincristine, ajmalicine, catharantine, vincoline, vincubine, vinorelbine, 
vindesine and serpentine. Those alkaloids that accumulated in different parts of the 
plant have important pharmacological value such as antitumor, sedative and 
antihypertensive (Rischer et al., 2006). Vinblastine, vincristine and vinorelbine were 
already being approved as therapeutic substances in United States while several other 
have been undergo clinical trials (Moudi et al., 2013). The most valuable alkaloids of C. 
roseus are the vinblastine and vincristine as they have the anticancer properties. These 
alkaloids are accumulated in the leaves or aerial parts of the plant and being produced in 
low amount by the plants (Rischer et al., 2006, Dutta et al., 2005). They are the first 
natural drugs that were used in the treatment of cancer and commonly been used 
together with the chemotherapy drugs in cancer therapy (Maria et al., 2008). Vinblastine 
Figure 2.1: Catharanthus roseus plant. Figure is taken from Nejat et al. 
(2015) 
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was approved as a part of treatment of testicular carcinoma, Hodgkin and non-Hodgkin 
lymphoma, breast cancer and tumour of germ cell. Vincristine was used as treatment for 
acute lymphoblastic leukemia, Wilm’s tumor in children, neuroblastoma, 
rhabdomyosarcoma, Hodgkin lymphoma and other lymphomas (Moudi et al., 2013).  
 
The mechanism of actions of these alkaloids is by interacting with tubulin and 
disrupting the mitotic spindle apparatus of the microtubules. This interaction cause 
blocking in mitosis process and lead the cancer cell to metaphase arrest (Chun-Hua 
Wang et al., 2012). Since these alkaloids interact and disrupt the microtubules, they can 
be highly toxic not only to cancer cell but also to non-malignant cell as microtubules 
involve in many cell functions (Moudi et al., 2013). Therefore, many side effects being 
reported that consist of vomiting, toxicity of nervous system and white blood cells, 
suppression of the activity of bone marrow, dyspenia, kidney problems, damage of liver 
cell, mouth ulcer, constipation, nausea, fever, urinary retention, abdominal cramps, and 
hair loss or alopecia. Hence, the usage of these alkaloids should be under controlled and 
correct dosage must be prescribed in order to minimize the side effects (Moudi et al., 
2013, Nejat et al., 2015). 
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CHAPTER 3 
MATERIALS AND METDODS 
3.1   Materials  
All autoclavable materials including glassware and plastic ware were sterilised and 
autoclaved at 121 °C for 30 minutes at a pressure of 100 kPA prior to use. 
 
3.2   Methods 
3.2.1   Preparation of C. roseus aqueous extract 
The method of extraction was performed as according to Nor Hazwani et al. (2010). C. 
roseus plants were collected from Teluk Air Tawar, Butterworth, Penang. The plant 
specimen was sent for identification at Herbarium Unit, School of Biological Sciences, 
Universiti Sains Malaysia (USM). The voucher specimen identification of the plant is 
10933. The fresh leaves were washed and dried in 40 ˚C oven. The dried leaves were 
grounded into powder and 50 gm was dissolved in 1 L distilled water. The mixture was 
incubated for 24 hours in water bath shaker at 40 oC. The mixture was centrifuged for 
15 minutes at 860 × g before filtered by using Whatmann filter paper No 1 (Sartorius, 
Germany) . Then, the extract was freeze dried in freeze dryer (FDU-1200, Eyela, USA) 
and was kept in -20 oC for storage and ready to be used. 
 
3.2.2   Synthesis of C. roseus-AgNPs. 
The AgNPs has been synthesised, optimised and characterised previously. Five mL of 
10% C. roseus aqueous extract (w/v) was dissolved with 45mL of 5 mM silver nitrate 
(AgNO3) solution. The solution was left at room temperature for 24 hours until a 
brown-yellow solution was formed. The brown-yellow solution was the sign of the 
presence of AgNPs. The solution was centrifuged at 7700 × g for 15 min. The 
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supernatant was discarded and the pellets were washed with distilled water two times 
before dried in oven for 48 hours at 40 oC. The characteristics of C. roseus-AgNPs that 
were used in this study were summarized as below: 
Characterizatios C. roseus-AgNPs 
Synthesis 10% of C. roseus aqueous extracts in 5 mM of 
AgNO3 
Surface Plasmon (UV-Vis 
spectroscopy) 
500 nm 
Transmission Electron (TEM) Shape : Spherical and uniform 
Size : 20 nm to 50 nm 
Diameter : 30 nm 
Particle Size and Zeta 
Potential Measurement 
Mean particle size: 167 nm 
Zeta potential : 0.0295 mV 
X-ray Diffraction (XRD) 
analysis 
Spectrum 2θ values : 38.12º, 44.31º, 64.45º and 
77.41º 
Plane : 111, 200, 220 and 311 
Structure : Crystals in nature 
 
3.2.3   Preparation of complete media  
Jurkat and HT29 cells were cultured in a complete Roswell Park Memorial Institute-
1640 (RPMI-1640) (Nacalai Tesque, Japan) medium. Two gram sodium bicarbonate 
(Sigma, USA) was weighted and mixed well with 900 mL of Ultra-Pure Water in a 
conical flask. Ultra-Pure Water was added until up to 1 L after the pH of the solution 
was adjusted to pH 7.1. The medium was filtered sterilised by using 0.22 µm disposable 
filter system that connected with vacuum pump in the Class II Biosafety Cabinet.  Five 
mL of the prepared medium was put into 25 cm2 flask and incubated for 24 hours in the 
incubator (Shellab, USA) at 37 oC with 5% CO2. The sterility of the prepared medium 
was checked before proceed to produce complete medium. The medium were added 
with 10% heat-inactivated fetal bovine serum (v/v) (Nacalai Tesque, Japan), 1% of 100 
units/mL penicillin-streptomycin (v/v) (Nacalai Tesque, Japan) and 1% of 200 mM-L-
Glutamine Stock Solution (v/v) (Nacalai Tesque, Japan) as supplements to make it a 
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complete medium. Prior to use, the fetal bovine serum was heat-inactivated in 56 oC 
water bath for 30 min. 
 
3.2.4   Freezing cells 
The confluency of Jurkat and HT29 cells were checked under inverted microscope 
(Carl-Zeiss, USA). The cells were taken out from the 25 cm2 culture flask and 
transferred into a 15 mL centrifuge tube (BD Biosciences, USA) after reaching 70 to 
80% confluency. HT29 cells were detached first by using 1mL 2.5 g/l-Trypsin/1mmol/l-
EDTA solution (Nacalai Tesque, Japan). The cells were centrifuged at 500 × g for 5 
minutes. The supernatant was removed and the pellet was resuspend with ice cold 
freezing medium which contains the mixture of 10% dimethyl sulphoxide (DMSO) 
(v/v) and 90% of fetal bovine serum (v/v). The mixture was aliquot into sterile 1.8 mL 
cryotube vials (Nunc, Denmark) and was put in a container before stored in -80 oC 
freezer for overnight. After that, the cells were transferred to the liquid nitrogen storage 
tank.  
 
3.2.5   Thawing cells 
Frozen cells from liquid nitrogen tank were immediately immersed in a water bath at 37 
oC. The semi-fluid cells suspension were diluted in pre-warmed complete RPMI-1640 
growth medium (Nacalai Tesque, Japan) and centrifuged at 500 × g for 10 minutes. The 
DMSO containing supernatant was then discarded and the pellet was resuspend with 
pre-warmed complete RPMI-1640 growth medium before transferred into 25 cm2 tissue 
culture flask. The cells suspension was then incubated in the incubator (Shellab, USA) 
at 37 oC with 5% CO2. Cells were routinely checked under inverted microscope (Carl-
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Zeiss, USA) to determine the confluency. The cells were subculture when the cells 
reached 70 to 80% confluence. 
 
3.2.6   Subculturing cells  
Jurkat and HT29 cell lines were obtained from American Type Culture Collection 
(ATCC). The cells was maintained in complete medium of RPMI-1640 containing 10% 
heat-inactivated fetal bovine serum (v/v), 1% of 100 units/mL penicillin-steptomycin 
(v/v) and 1% of L-glutamine (v/v). Cells were routinely observed under inverted 
microscope to make sure that no signs of contaminations of bacteria or fungi. The 
culture medium was change in every 3 days to maintain the good condition for the cells. 
Jurkat cells were taken out from the 25 cm2 culture flask and transferred into a 15 mL 
centrifuge tube (BD Biosciences, USA). HT29 cells were detached first by using 1mL 
2.5g/l-Trypsin/1mmol/l-EDTA solution. The cells were centrifuged at 500 × g for 5 
minutes. The supernatant was discarded and the pellet was resuspend with new 
complete RPMI-1640 medium and transferred back into the larger culture flask. Then, 
the flask containing cells were incubated in the incubator at 37 oC with 5% CO2. Cells 
were grown until reached 70 to 80% confluency before used in experiments. 
 
3.2.7   MTS Assay 
Cell proliferation was assessed by using Cell Titer 96® AQueous Non-Radioactive Cell 
Proliferation Assay kit (Promega, USA) which composed of [3-(4, 5-dimethylthiazol-2-
yl)-5-(3-carbonxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium/phenazine metho 
sulphate; MTS] and (phenazine methosulfate; PMS). The procedures were carried out as 
stated in the protocol of the kit. Jurkat and HT29 cells were seeded in a 96-well plate at 
a density of 4 × 105 cell/mL and 1 × 105 cell/mL, respectively. Cells were treated with 
23 
 
C. roseus-AgNPs and C. roseus aqueous extract in serial dilution manner which were 
1.96 µg/ml, 3.91 µg/ml, 7.82 µg/ml, 15.63 µg/ml, 31.25 µg/ml, 62.5 µg/ml, 125 µg/ml, 
250 µg/ml, 500 µg/ml and 1000 µg/ml in 96-well plates. The cells were incubated in an 
incubator for 24, 48 and 72 hours. Cells also were treated with silver nitrate (AgNO3) of 
concentration 1000 µg/ml. Camptothecin at a concentration of 1.25 µg/ml was used as a 
positive control and the untreated cells were used as negative control. Each of the 
sample size was in triplicate. Following the incubation time interval, the cultured cells 
in each well were added with 20 µL of mixture of MTS/PMS solution with the ratio of 
20:1. The cells were then incubated for 1 to 4 hours at 37 oC in a humidified 5% CO2 
incubator. The 96-well plates were analysed at 490 nm using ELISA plate reader (Bio 
Tek, USA). The half minimal inhibitory concentration (IC50) values were determined 
from the graph to get the treatment concentration that caused 50% cell death. The cell 
viability (%) was calculated as follows: 
Percentage Cell Viability (%) =       Mean OD of treated cells    ×  100 
            Mean OD of untreated (control) cells 
Where, OD is the optical density. 
 
3.2.8   Annexin V-FITC/Propidium Iodide Assay 
The externalised phosphatidylserine phospholipid was examined by using Annexin V-
FITC/PI apoptosis detection kit (BD Biosciences, USA). The protocol used was carried 
out as stated in the manual. Cells at a concentration of 4 × 105 cells/mL for Jurkat and 5 
× 105 cells/mL for HT29 were treated with three different concentrations (5 µg/mL, 10 
µg/mL, 15 µg/mL) of either C. roseus-AgNPs or C. roseus aqueous extract and 1000 
µg/mL of AgNO3 solution for 6, 24, 48 and 72 hours. Camptothecin with concentration 
of 1.25 µg/mL was used as a positive control and untreated cells as negative control. 
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The cells were harvested and washed twice with 1X cold phosphate buffered saline 
(PBS) (Sigma-Aldrich, USA). Then, the cells were centrifuged at 500 × g for 5 minutes 
before resuspend with 100 µL of 1X binding buffer (0.1 M Hepes (pH 7.4), 1.4 M 
NaCl, 25 mM CaCl2) at a concentration of 1 × 106 cells/mL. Approximately 100 µL cell 
solutions were transferred into 5mL round bottom culture tube (BD Biosciences, USA). 
Five µL of Annexin V-FITC and 5 µL of Propidium Iodide (PI) were added to stain the 
cells.  The cells were gently mixed by using vortex and incubated at room temperature 
in the dark for 15 min before added with 1X binding buffer (400 µL) to stop the 
reaction. The stained cells were analyzed by FacsCalibur flow cytometry (BD 
FACSCalibur Flow cytometry, US) at 10,000 events. 
 
3.2.9   Cell Cycle Analysis 
Cell cycle arrested were analyse using Cycle TestTM Plus DNA Reagent Kit and DNA 
QC Particles (Becton Dickinson, USA) and the proceduresl was carried out following 
the manufacturers’ recommendation. Jurkat and HT29 cells at concentration of 4 × 105 
cells/mL and 5 × 105 cells/mL, respectively were treated with 10 µg/mL C. roseus-
AgNPs or C. roseus aqueous extract and 1000 µg/mL of AgNO3 solution. The cells 
were incubated in the incubator at 37 oC in 5% CO2 humidified atmosphere for 24, 48 
and 72 hours. Untreated cells were used as negative control and camptothecin with 
concentration of 1.25 µg/mL was used as positive control. After each incubation hour, 
cells were harvested and washed with buffer solution three times. The cells were 
counted and the concentration was adjusted to 5 × 105 cells. The cell suspensions were 
centrifuge at 400 × g for 5 minutes. The supernatant was discarded and 250 µL of 
Solution A (trypsin buffer) was added and mixed gently before being left for 10 minutes 
at room temperature. 200 µL of Solution B (trypsin inhibitor and RNase buffer) were 
